Full text is available at the source.
Abstract
Glucagon-like peptide-1 (GLP-1) is indicated in the treatment of type 2 diabetes mellitus and may influence reward processing.
- GLP-1 is associated with reward processing, which is crucial for various mental disorders.
- Preclinical research indicates that GLP-1 receptor mono-agonists (GLP-1RAs) could potentially affect reward function.
- Emerging evidence suggests that GLP-1 and GLP-1RAs may serve as treatment strategies for certain mental disorders.
Simplified